UK industry optimistic about value based pricing proposals
This article was originally published in SRA
The Association of the British Pharmaceutical Industry said on 14 March it was optimistic that a new value based pricing system in the UK is a chance to right old wrongs, but it warns the devil is in the detail1.
You may also be interested in...
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.